Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow HERON THERAPEUTICS, INC. /DE/

Get SEC filing alerts via email and in your feed for HERON THERAPEUTICS, INC. /DE/

HRTX

HERON THERAPEUTICS, INC. /DE/

About HERON THERAPEUTICS, INC. /DE/

Heron Therapeutics, Inc. is a biotechnology company focused on developing and commercializing innovative therapies for acute care and oncology patients. Its portfolio includes products like ZYNRELEF for postoperative pain, APONVIE for nausea, and antiemetics CINVANTI and SUSTOL. The company leverages proprietary drug delivery technology, operates in regulated markets, and relies on third-party manufacturing and patent protections to maintain its competitive position.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from HERON THERAPEUTICS, INC. /DE/

1
1
HERON THERAPEUTICS, INC. /DE/ Heron Therapeutics Reports $8.1 Million Net Loss in Q1 2026

Via official filing (AI summary) | 25 days ago | 0 comments

2
1
HERON THERAPEUTICS, INC. /DE/ Heron Therapeutics Reports $20.2 Million Net Loss and 7.4% Revenue Growth for Fiscal Year 2025

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
HERON THERAPEUTICS, INC. /DE/ Heron Therapeutics Reports 16.5% Revenue Growth in Q3 2025

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
HERON THERAPEUTICS, INC. /DE/ Heron Therapeutics Reports Q2 2025 Financial Results with Increased Sales and Improved Gross Margin

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
HERON THERAPEUTICS, INC. /DE/ Heron Therapeutics Reports $2.6 Million Net Income and 12.4% Revenue Growth in Q1 2025

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
HERON THERAPEUTICS, INC. /DE/ Heron Therapeutics Reports $13.6M Net Loss, 13.6% Revenue Growth in 2024

Via official filing (AI summary) | over 1 year ago | 0 comments

7
1
HERON THERAPEUTICS, INC. /DE/ Heron Therapeutics Reports Improved Revenue and Reduced Losses in Q3 2024

Via official filing (AI summary) | over 1 year ago | 0 comments